Welcome to our dedicated page for EMBLA news (Ticker: EMBLA), a resource for investors and traders seeking the latest updates and insights on EMBLA stock.
Embla Medical (EMBLA) delivers innovative mobility solutions through advanced prosthetics and neuro orthotics. This news hub provides investors and healthcare professionals with essential updates on product developments, regulatory milestones, and strategic initiatives shaping the medical devices sector.
Track official press releases covering earnings reports, clinical research findings, and new product approvals. Our curated collection features updates on bionic limb innovations, Medicare coverage changes, and global expansion efforts – all critical for understanding EMBLA's market leadership in rehabilitative technologies.
Discover timely information on key business areas including prosthetic device enhancements, neuro orthotic clinical trials, and partnerships with healthcare providers. The archive serves as a definitive resource for analyzing EMBLA's commitment to improving patient outcomes through evidence-based solutions.
Bookmark this page for direct access to verified company announcements. Check regularly for updates on regulatory compliance achievements, technological breakthroughs in mobility devices, and financial performance metrics essential for informed decision-making.
Embla Medical (EMBLA) reported Q2 2025 financial results with sales of USD 232 million, showing 7% reported growth and 5% organic growth. The company's EBITDA margin reached 21% in Q2 2025, with net profit growing 5% to USD 21 million.
The Prosthetics & Neuro Orthotics segment demonstrated strong performance with 9% organic growth, while Bracing & Supports declined 2% and Patient Care remained flat. The company has narrowed its full-year organic sales growth guidance to 5-6% (from 5-8%) and maintained EBITDA margin guidance at 20-21%.
Notable developments include an agreement to acquire 51% stake in Streifeneder ortho.production, a new US reimbursement code for NEURO HiTRONIC MPKAFO, and a EUR 50 million loan from Nordic Investment Bank.
Embla Medical (NASDAQ:EMBLA) has signed an agreement to acquire a 51% majority stake in Streifeneder ortho.production GmbH, a German-based international developer and supplier of orthopaedic mobility solutions. Streifeneder, which generated sales of EUR 25 million in 2024, employs approximately 100 people and specializes in prosthetic and orthotic components.
The strategic investment aligns with Embla Medical's Growth'27 strategy, positioning the company as a full-range solutions provider in the global O&P market. As part of the transaction, Embla Medical will issue 2,805,135 new shares valued at DKK 33.26 per share, totaling DKK 93 million (EUR 12.5 million). The sellers will be subject to a two-year lock-up period.
Embla Medical reported Q4 2024 sales of USD 225 million with 5% organic growth and 8% local currency growth. The company's Prosthetics & Neuro Orthotics segment grew 12% organically, while Bracing & Supports increased 2%, and Patient Care declined 1%.
Q4 2024 highlights include a gross profit margin of 63% (up from 61% in Q4 2023), EBITDA margin of 21% (up from 18%), and net profit of USD 19 million. Free cash flow reached USD 34 million, representing 15% of sales.
For full-year 2024, the company achieved 6% organic growth, with EBITDA margin reaching 20%. Looking ahead, Embla Medical issued 2025 guidance projecting 5-8% organic sales growth and 20-21% EBITDA margin.
Embla Medical reported solid Q3 2024 results with sales of USD 214 million, representing 7% organic growth and 11% reported growth. The company saw strong performance in EMEA, driven by Prosthetics & Neuro Orthotics and Patient Care. EBITDA margin was strong at 22%, benefiting from cost reduction initiatives and improved product mix.
Key highlights include:
- Gross profit margin improved to 63% from 62% in Q3 2023
- Net profit grew by 58% to USD 22 million
- Free cash flow was 15% of sales
- NIBD/EBITDA before special items was 2.8x
Embla Medical reiterated its full-year guidance of 6-8% organic sales growth and ~20% EBITDA margin before special items. The company continues to execute its Growth'27 strategy and is preparing for the full launch of new bionic knee solutions in early 2025.
Embla Medical reported its highest ever quarterly sales of USD 217 million in Q2 2024, with 6% organic growth. The company's EBITDA was USD 47 million with a 22% EBITDA margin. Strong performance was noted in Prosthetics & Neuro Orthotics and Patient Care, particularly in EMEA. Medicare in the US finalized a proposal granting active K2 patients access to prosthetic knees, effective September 1, 2024. Embla launched two new bionic knee products: NAVii® by Össur and Icon® by College Park. The company narrowed its full-year guidance to 6-8% organic sales growth and ~20% EBITDA margin before special items. Embla also announced plans to unite its Patient Care facilities under a new brand, ForMotion™.
Embla Medical (Nasdaq Copenhagen: EMBLA) announced that the Centers for Medicare & Medicaid Services has expanded access to high activity K3 knees for active K2 lower-limb amputees in the United States. This decision, effective September 1, 2024, allows a large patient group to access bionic knee technology, previously restricted to K3 and K4 functional level amputees.
The policy change follows extensive research showing that advanced prosthetic devices lead to significant clinical benefits for active K2 amputees, including reduced fall rates and improved mobility. To qualify, healthcare professionals must document that a bionic knee would improve the patient's functional health outcomes. The coverage may also include access to compatible high active K3 foot solutions.
Embla Medical's CEO, Sveinn Sölvason, welcomed the decision, stating it will greatly improve the lives of active K2 lower-limb amputees, helping them become more independent in daily activities.
